Ustekinumab biosimilar for Plaque psoriasis


featured image

Ustekinumab biosimilar (ABP-654) is a biosimilar medicine of an approved monoclonal antibody (ustekinumab) and is proposed for the treatment of moderate to severe plaque psoriasis in adults. Plaque psoriasis is the most common type of psoriasis and is an inflammatory skin disease that typically follows a relapsing and remitting course.

Indications: Plaque psoriasis
Therapeutic Areas: Dermatology
Year: 2022

Ustekinumab biosimilar (ABP-654) is a biosimilar medicine of an approved monoclonal antibody (ustekinumab) and is proposed for the treatment of moderate to severe plaque psoriasis in adults. Plaque psoriasis is the most common type of psoriasis and is an inflammatory skin disease that typically follows a relapsing and remitting course. Plaque psoriasis is characterised by dry red skin lesions (called plaques) covered in silver scales which commonly appear on the elbows, knees, scalp and lower back. The plaques can be itchy and sore and in severe cases the skin may crack and bleed. Biosimilar medicines are biological therapies which have no clinically meaningful differences in efficacy, quality, and safety compared to the reference biologic product. Biosimilars are competitively priced to compete with the original medicinal product allowing them to be more widely available to the patients who need them.